LON:DPH

Dechra Pharmaceuticals PLC (DPH.L) Share Forecast, Price & News

GBX 3,570

-32.00 (-0.89 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

3,475

Now: GBX 3,570▼

3,623.36

50-Day Range

3,182

MA: GBX 3,383.89▼

3,602

52-Week Range

2,030

Now: GBX 3,570▼

3,652

Volume225,456 shs

Average Volume258,147 shs

Market Capitalization£3.86 billion

P/E Ratio108.84

Dividend Yield0.98%

BetaN/A

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

MarketRank^™

Overall MarketRank^™

0.71 out of 5 stars

1.3 Analyst's Opinion

Consensus Rating
Dechra Pharmaceuticals PLC (DPH.L) has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 3,077.50, Dechra Pharmaceuticals PLC (DPH.L) has a forecasted downside of 13.8% from its current price of GBX 3,570.
Amount of Analyst Coverage
Dechra Pharmaceuticals PLC (DPH.L) has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
Dechra Pharmaceuticals PLC (DPH.L) has received 336 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Dechra Pharmaceuticals PLC (DPH.L) has received 386 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Dechra Pharmaceuticals PLC (DPH.L) has received 53.46% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals PLC (DPH.L) and other stocks. Vote “Outperform” if you believe DPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Dechra Pharmaceuticals PLC (DPH.L) has a dividend yield of 0.98%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dechra Pharmaceuticals PLC (DPH.L) does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Dechra Pharmaceuticals PLC (DPH.L) is 103.66%. Payout ratios above 75% are not desirable because they may not be sustainable.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dechra Pharmaceuticals PLC (DPH.L) insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £10,350,000 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Dechra Pharmaceuticals PLC (DPH.L) is 108.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.99.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dechra Pharmaceuticals PLC (DPH.L) is 108.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.74.
Price to Book Value per Share Ratio
Dechra Pharmaceuticals PLC (DPH.L) has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Major

Sub-IndustryN/A

SectorMedical

Current SymbolLON:DPH

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.dechra.com

Phone+44-1606-814730

Employees1,889

Debt

Debt-to-Equity Ratio55.69

Current Ratio3.27

Quick Ratio2.37

Price-To-Earnings

Trailing P/E Ratio108.84

Forward P/E Ratio0.36

P/E GrowthN/A

Sales & Book Value

Annual Sales£515.10 million

Price / Sales7.49

Cash FlowGBX 209.91 per share

Price / Cash Flow17.01

Book ValueGBX 590.20 per share

Price / Book6.05

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares108,142,000

Market Cap£3.86 billion

Next Earnings Date2/22/2021 (Estimated)

OptionableNot Optionable

GBX 3,570

-32.00 (-0.89 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

Dechra Pharmaceuticals PLC (DPH.L) (LON:DPH) Frequently Asked Questions

How has Dechra Pharmaceuticals PLC (DPH.L)'s stock been impacted by COVID-19?

Dechra Pharmaceuticals PLC (DPH.L)'s stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DPH stock has increased by 44.4% and is now trading at GBX 3,570.
View which stocks have been most impacted by COVID-19.

Is Dechra Pharmaceuticals PLC (DPH.L) a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals PLC (DPH.L) in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dechra Pharmaceuticals PLC (DPH.L) stock.
View analyst ratings for Dechra Pharmaceuticals PLC (DPH.L) or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Dechra Pharmaceuticals PLC (DPH.L)?

Wall Street analysts have given Dechra Pharmaceuticals PLC (DPH.L) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dechra Pharmaceuticals PLC (DPH.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Dechra Pharmaceuticals PLC (DPH.L)'s next earnings date?

Dechra Pharmaceuticals PLC (DPH.L) is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Dechra Pharmaceuticals PLC (DPH.L).

How often does Dechra Pharmaceuticals PLC (DPH.L) pay dividends? What is the dividend yield for Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L) declared a dividend on Monday, September 7th. Investors of record on Thursday, November 5th will be paid a dividend of GBX 24 per share on Friday, November 27th. This represents a dividend yield of 0.73%. The ex-dividend date is Thursday, November 5th. This is a positive change from Dechra Pharmaceuticals PLC (DPH.L)'s previous dividend of GBX 10.29. The official announcement can be seen at this link.
View Dechra Pharmaceuticals PLC (DPH.L)'s dividend history.

Is Dechra Pharmaceuticals PLC (DPH.L) a good dividend stock?

Dechra Pharmaceuticals PLC (DPH.L) pays an annual dividend of GBX 34 per share and currently has a dividend yield of 0.98%. The dividend payout ratio of Dechra Pharmaceuticals PLC (DPH.L) is 103.66%. Payout ratios above 75% are not desirable because they may not be sustainable.
View Dechra Pharmaceuticals PLC (DPH.L)'s dividend history.

What price target have analysts set for DPH?

4 brokerages have issued 1-year price objectives for Dechra Pharmaceuticals PLC (DPH.L)'s stock. Their forecasts range from GBX 2,510 to GBX 3,515. On average, they expect Dechra Pharmaceuticals PLC (DPH.L)'s stock price to reach GBX 3,077.50 in the next year. This suggests that the stock has a possible downside of 13.8%.
View analysts' price targets for Dechra Pharmaceuticals PLC (DPH.L) or view Wall Street analyst' top-rated stocks.

Who are some of Dechra Pharmaceuticals PLC (DPH.L)'s key competitors?

Some companies that are related to Dechra Pharmaceuticals PLC (DPH.L) include Hutchison China MediTech Limited (HCM.L) (HCM), Vectura Group plc (VEC.L) (VEC), Beximco Pharmaceuticals Limited (BXP.L) (BXP), ECO Animal Health Group plc (EAH.L) (EAH), Allergy Therapeutics plc (AGY.L) (AGY), Trilogy International Partners Inc. (TRL.TO) (TRL), Sareum Holdings plc (SAR.L) (SAR), Futura Medical plc (FUM.L) (FUM), Avivagen Inc. (VIV.V) (VIV), N4 Pharma Plc (N4P.L) (N4P), Cathay International Holdings Limited (CTI.L) (CTI), Antisense Therapeutics Limited (ANP.AX) (ANP), Bayer Aktiengesellschaft (BAYN.F) (BAYN), Mayne Pharma Group (MAYNF) and Mayne Pharma Group Limited (MYX.AX) (MYX).
View all of DPH's competitors.

What other stocks do shareholders of Dechra Pharmaceuticals PLC (DPH.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals PLC (DPH.L) investors own include (TTR.L) (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion plc (JD.L) (JD), Ashtead Group plc (AHT.L) (AHT), Cranswick plc (CWK.L) (CWK), Drax Group plc (DRX.L) (DRX), RPC Group (RPC), Robert Walters plc (RWA.L) (RWA), SEB SA (SKP.L) (SKP) and Barratt Developments plc (BDEV.L) (BDEV).

Who are Dechra Pharmaceuticals PLC (DPH.L)'s key executives?

Dechra Pharmaceuticals PLC (DPH.L)'s management team includes the following people:

Mr. Ian D. Page, CEO, MD & Exec. Director (Age 59, Pay $793k)
Mr. Paul Nicholas Sandland MAAT, FCCA, CFO & Exec. Director (Age 41, Pay $375.6k)
Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 57, Pay $466k)
Dr. Susan Longhofer, Chief Scientific Officer (Age 62)
Ms. Katy Clough, Group HR Director
Mr. Mike Eldred, Pres of North America (Age 50)
Ms. Melanie Hall, Company Sec.

What is Dechra Pharmaceuticals PLC (DPH.L)'s stock symbol?

Dechra Pharmaceuticals PLC (DPH.L) trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals PLC (DPH.L)?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals PLC (DPH.L)'s stock price today?

One share of DPH stock can currently be purchased for approximately GBX 3,570.

How big of a company is Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L) has a market capitalization of £3.86 billion and generates £515.10 million in revenue each year. Dechra Pharmaceuticals PLC (DPH.L) employs 1,889 workers across the globe.

What is Dechra Pharmaceuticals PLC (DPH.L)'s official website?

The official website for Dechra Pharmaceuticals PLC (DPH.L) is www.dechra.com.

How can I contact Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L)'s mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here